Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.
| Image |  |
|---|---|
| Description | scientific article published on 4 April 2017 |
| Author/s |
author: Melanie C Dispenza Bruce S. Bochner |
| Publication date | April 4, 2017 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |